Telesta Therapeutics Receives Complete Response Letter from FDA
MONTREAL, Feb. 2, 2016 -- (Healthcare Sales & Marketing Network) - Telesta Therapeutics Inc. (TST.TO) (BNHLF) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter to Telesta's Biologics License Applicatio... Biopharmaceuticals, Oncology, FDATelesta Therapeutics, MCNA, bladder cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Bladder Cancer | Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | Marketing | Pharmaceuticals